ClinicalTrials.gg
CompletedNCT05234736Updated May 22, 2026Results posted

A Study to Evaluate the Pharmacokinetic Profile of CBL-514 Injection in Healthy Volunteers

A Phase 2 interventional study of CBL-514 in Subcutaneous Fat, sponsored by Caliway Biopharmaceuticals Co., Ltd.. Completed at 1 site in United States. Open to participants aged 18 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-22.

Sponsored by Caliway Biopharmaceuticals Co., Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years to 64 Years
Sex
All
01

Study summary

This Phase 2 study will be an open-label and single course study to assess the safety, tolerability, PK and metabolite profile of CBL-514.

Read the detailed description

This is a Phase 2 study to evaluate the safety, tolerability, PK and metabolite profile of CBL-514 injection at the maximal use dosage.

This Phase 2 study has an open-label and single course design. A total of 10 adult participants, composed of 5 females and 5 males, will be enrolled in a single cohort. Each participant will receive a single course of treatment with CBL-514 800 mg on the abdomen (administered as multiple subcutaneous injections) on Day 1 only.

02

Conditions studied

  • Subcutaneous Fat
03

In context

Lead sponsor

Caliway Biopharmaceuticals Co., Ltd. is the lead sponsor of 16 studies on the registry; 5 are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 4 (44%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male/female aged 18 years to 64 years old (at Screening), inclusive.
  2. (BMI) >18.5 and \< 35 kg/m2 and body weight ≥ 50 kg at Screening and Day 1.
  3. Participant has sufficient subcutaneous fat thickness of at least 3.00 cm (30.0 mm) measured by caliper skinfold method around treatment area at Screening and Day 1.
  4. Voluntarily signs the Form (ICF) and, in the opinion of the Investigator or delegate, is physically and mentally capable of participating in the study, and willing to adhere to study procedures, including food and drink restrictions.

Exclusion criteria

Exclusion Criteria:

  1. Women of (WOCBP) who are not willing to commit to an acceptable regimen from the time of Screening and throughout study participation until 90 days after the last IP dose, or who are currently pregnant or lactating. Male participants who are not willing to commit to an acceptable contraceptive method. Female participants who are not WOCBP are not required to use contraception.
  2. Participant diagnosed with coagulation disorders or is receiving anticoagulant/antiplatelet therapy or medications or dietary supplements, which impede coagulation or aggregation.
  3. Participant has (HbA1c) ≥ 9%, delayed wound healing, or any diabetic risks which, in the opinion of Investigator, is inappropriate to participate in the study.
  4. Participant has a cardiovascular disease and clinically significant abnormal findings in (ECG).
  5. Participant with active or prior history of within 5 years before Screening or being worked-up for a possible malignancy. Except adequately treated basal cell carcinoma of skin and in situ squamous cell carcinoma of skin would be eligible as per Investigator's discretion.
  6. Participant with a history of (HIV)-1, , or infections or participants with active HIV, hepatitis B, or hepatitis C infections at Screening:
  7. Participants with positive COVID-19 antigen test at Screening and Day 1.
  8. Participants with any hepatic medical condition that, in the opinion of the Investigator, would compromise the participant's ability to undergo study procedures and/or interfere with the assessment of the obtained data.
  9. Participants with a history of trypanophobia, the extreme fear of medical procedures involving injections or needles, or who experience vasovagal syncope and faint or pass out at the sight of blood or a needle.
  10. Participant has abnormal skin or local skin conditions at the treatment area, which in the opinion of Investigator, is inappropriate to participate in the study, including but not limited to any of the following:
  11. Participant who has the following procedures:

    1. Previous surgery which caused scar tissues on the anticipated treatment area before Screening or during the study,
    2. Liposuction to the region to be treated before Screening or during the study,
    3. Esthetic procedure e.g., cryolipolysis, ultrasonic lipolysis, LLLT, lipolysis injection to the region to be treated within 12 months before Screening or during the study.
  12. Participant is undergoing chronic systemic or therapy.
  13. Requiring continual use of the following therapeutic agents during the study: terfenadine, buspirone, fexofenadine, any medication that is known to strongly inhibit or induce CYP enzymes, sensitive CYP substrates or drugs with narrow therapeutic index, in the opinion of the Investigator, may affect the evaluation of the study product or place the participant at undue risk.

    If a participant needs to use the above-mentioned therapeutic agents during the study for any reason, these therapeutic agents should not be used for at least 2 days prior to dosing and until 1 day post-dose.

  14. Unable to receive local anesthesia (e.g., history of to lidocaine).
  15. Participants with known allergies or sensitivities to the IP or its components.
  16. Participants with liver cirrhosis or with inadequate liver function at Screening defined as (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), total (TBIL), or gamma-glutamyl transferase (GGT) > 3.0 × (ULN).
  17. Participants with any renal impairment, defined as abnormal serum creatinine, and urea > 1.5 × ULN or estimated (eGFR) \< 90 mL/min/1.73 m2. Participants who are currently on dialysis should be excluded.

    Participants with an eGFR ≥ 60 and \< 90 mL/min/1.73 m2 at Screening should be evaluated by the Investigator to exclude pre-existing renal disease or associated dysfunction. If mild decrease in eGFR is assessed by the Investigator as not clinically significant or not related to dysfunction, the subjects may be eligible upon the Investigator's assessment.

  18. Use of other drug or device within 4 weeks prior to Screening.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    CBL-514

    All 10 participants enrolled in the study will receive a single course of treatment with CBL-514 800 mg (unit dose: 2.0 mg/cm\^2) on the abdomen (administered as multiple subcutaneous injections) on Day 1 only.

    Drug: CBL-514

Interventions

  • CBL-514 800 mg (unit dose: 2.0 mg/cm\^2)

06

What researchers measure

Primary outcomes

  1. Assess Maximum Analyte Concentration of CBL-514 in Plasma (Cmax)

    To evaluate maximum analyte concentration of CBL-514 in plasma (Cmax) after single dose injection.

    Time frame: pre-dose, 1 hour, 2 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 10 hours, 12 hours, 18 hours, and 24 hours post-dose

  2. Assess Time to Cmax of CBL-514 in Plasma (Tmax)

    To evaluate time to Cmax of CBL-514 in plasma (tmax) after single dose injection.

    Time frame: pre-dose, 1 hour, 2 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 10 hours, 12 hours, 18 hours, and 24 hours post-dose

  3. Assess Area Under the Concentration-time Curve of CBL-514 in Plasma (AUC)

    To evaluate area under the concentration-time curve of CBL-514 in plasma (AUC) after single dose injection.

    Time frame: pre-dose, 1 hour, 2 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 10 hours, 12 hours, 18 hours, and 24 hours post-dose

  4. Assess Elimination Half-life of CBL-514 in Plasma (t1/2)

    To evaluate elimination half-life of CBL-514 in plasma (t1/2) after single dose injection.

    Time frame: pre-dose, 1 hour, 2 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 10 hours, 12 hours, 18 hours, and 24 hours post-dose

  5. Assess Apparent Total Plasma Clearance of CBL-514 in Plasma (CL/F).

    To evaluate apparent total plasma clearance of CBL-514 (CL/F) after single dose injection.

    Time frame: pre-dose, 1 hour, 2 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 10 hours, 12 hours, 18 hours, and 24 hours post-dose

  6. Assess Apparent Terminal Volume of Distribution of CBL-514 in Plasma (Vz/F).

    To evaluate apparent terminal volume of distribution of CBL-514 in plasma (Vz/F) after single dose injection.

    Time frame: pre-dose, 1 hour, 2 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 10 hours, 12 hours, 18 hours, and 24 hours post-dose

Secondary outcomes

  1. Number of Participants With Treatment-emergent Adverse Events (TEAEs) as Assessed by CTCAE v5.0

    Number of participants experiencing TEAEs

    Time frame: Day 1 to Week 4

  2. Number of Participants With Clinically Significant Abnormalities in Clinical Laboratory Values

    Clinical laboratory tests include Biochemistry, Hematology, Coagulation, Urinalysis, Virology and Pregnancy status test.

    Time frame: Up to 2 weeks after last treatment

07

Results

Posted May 22, 2026

Participant flow

Participant flow — Overall Study
MilestoneCBL-514
Started10
Completed10
Not completed0

Outcome measures

PrimaryAssess Maximum Analyte Concentration of CBL-514 in Plasma (Cmax)

To evaluate maximum analyte concentration of CBL-514 in plasma (Cmax) after single dose injection.

Time frame:
pre-dose, 1 hour, 2 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 10 hours, 12 hours, 18 hours, and 24 hours post-dose
Reported as:
Mean · ng/mL
Assess Maximum Analyte Concentration of CBL-514 in Plasma (Cmax)
ng/mLCurcumin of CBL-514Resveratrol of CBL-514
Assess Maximum Analyte Concentration of CBL-514 in Plasma (Cmax)137.6 ± 42.679.5 ± 18.0
PrimaryAssess Time to Cmax of CBL-514 in Plasma (Tmax)

To evaluate time to Cmax of CBL-514 in plasma (tmax) after single dose injection.

Time frame:
pre-dose, 1 hour, 2 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 10 hours, 12 hours, 18 hours, and 24 hours post-dose
Reported as:
Mean · hour
Assess Time to Cmax of CBL-514 in Plasma (Tmax)
hourCurcumin of CBL-514Resveratrol of CBL-514
Assess Time to Cmax of CBL-514 in Plasma (Tmax)7.4 ± 1.67.4 ± 1.8
PrimaryAssess Area Under the Concentration-time Curve of CBL-514 in Plasma (AUC)

To evaluate area under the concentration-time curve of CBL-514 in plasma (AUC) after single dose injection.

Time frame:
pre-dose, 1 hour, 2 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 10 hours, 12 hours, 18 hours, and 24 hours post-dose
Reported as:
Mean · hour*ng/mL
Assess Area Under the Concentration-time Curve of CBL-514 in Plasma (AUC)
hour*ng/mLCurcumin of CBL-514Resveratrol of CBL-514
Assess Area Under the Concentration-time Curve of CBL-514 in Plasma (AUC)881.4 ± 220.11005.0 ± 178.8
PrimaryAssess Elimination Half-life of CBL-514 in Plasma (t1/2)

To evaluate elimination half-life of CBL-514 in plasma (t1/2) after single dose injection.

Time frame:
pre-dose, 1 hour, 2 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 10 hours, 12 hours, 18 hours, and 24 hours post-dose
Reported as:
Mean · hour
Assess Elimination Half-life of CBL-514 in Plasma (t1/2)
hourCurcumin of CBL-514Resveratrol of CBL-514
Assess Elimination Half-life of CBL-514 in Plasma (t1/2)3.3 ± 0.97.2 ± 2.0
PrimaryAssess Apparent Total Plasma Clearance of CBL-514 in Plasma (CL/F).

To evaluate apparent total plasma clearance of CBL-514 (CL/F) after single dose injection.

Time frame:
pre-dose, 1 hour, 2 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 10 hours, 12 hours, 18 hours, and 24 hours post-dose
Reported as:
Mean · L/hour
Assess Apparent Total Plasma Clearance of CBL-514 in Plasma (CL/F).
L/hourCurcumin of CBL-514Resveratrol of CBL-514
Assess Apparent Total Plasma Clearance of CBL-514 in Plasma (CL/F).767.2 ± 253.8136.1 ± 20.1
PrimaryAssess Apparent Terminal Volume of Distribution of CBL-514 in Plasma (Vz/F).

To evaluate apparent terminal volume of distribution of CBL-514 in plasma (Vz/F) after single dose injection.

Time frame:
pre-dose, 1 hour, 2 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 10 hours, 12 hours, 18 hours, and 24 hours post-dose
Reported as:
Mean · L
Assess Apparent Terminal Volume of Distribution of CBL-514 in Plasma (Vz/F).
LCurcumin of CBL-514Resveratrol of CBL-514
Assess Apparent Terminal Volume of Distribution of CBL-514 in Plasma (Vz/F).3752.7 ± 1922.71255.2 ± 290.5
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs) as Assessed by CTCAE v5.0

Number of participants experiencing TEAEs

Time frame:
Day 1 to Week 4
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs) as Assessed by CTCAE v5.0
ParticipantsCBL-514
Number of Participants With Treatment-emergent Adverse Events (TEAEs) as Assessed by CTCAE v5.010
SecondaryNumber of Participants With Clinically Significant Abnormalities in Clinical Laboratory Values

Clinical laboratory tests include Biochemistry, Hematology, Coagulation, Urinalysis, Virology and Pregnancy status test.

Time frame:
Up to 2 weeks after last treatment
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Abnormalities in Clinical Laboratory Values
ParticipantsCBL-514
Number of Participants With Clinically Significant Abnormalities in Clinical Laboratory Values0

Adverse events

Collected over from enrollment until end of follow-up (Week 4). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CBL-5140/10 (0%)0/10 (0%)10/10 (100%)
Most frequent other events
Most frequent other events
EventCBL-514
Injection site reactionsGeneral disorders10/10

Baseline characteristics

Age, Continuous
Age, Continuous(years)CBL-514
Mean47.5 ± 10.7
Sex: Female, Male
Sex: Female, Male(Participants)CBL-514
Female5
Male5
Race (NIH/OMB)
Race (NIH/OMB)(Participants)CBL-514
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White10
More than one race0
Unknown or Not Reported0
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)CBL-514
Hispanic or Latino1
Not Hispanic or Latino9
Unknown or Not Reported0
08

Study locations

1 site
  • DermResearch Inc
    Austin, Texas 78759, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2022 to primary completion in Jun 2022, 3 months.

Results were first posted in May 2026, 3 years 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 23, 2021
First posted
Feb 10, 2022
StartActual
Feb 11, 2022
Primary completionActual
Jun 9, 2022
CompletionActual
Jun 9, 2022
Results first posted
May 22, 2026
Last update
May 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05234736
Responsible party
Sponsor
First posted
Feb 10, 2022
Start date
Feb 11, 2022
Primary completion
Jun 9, 2022
Completion
Jun 9, 2022
Results posted
May 22, 2026
Last update
May 22, 2026

Study contacts

Anne Sheu
study director · Caliway Biopharmaceuticals Co., Ltd.

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CBL-514

Start the discussion